Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
71 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Chemotherapy Induced Anemia - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Chemotherapy Induced Anemia - Pipeline Review, H2 2016', provides an overview of the Chemotherapy Induced Anemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Anemia and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Anemia - The report reviews pipeline therapeutics for Chemotherapy Induced Anemia by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Chemotherapy Induced Anemia therapeutics and enlists all their major and minor projects - The report assesses Chemotherapy Induced Anemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Anemia Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Anemia - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Anemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Chemotherapy Induced Anemia Overview 8 Therapeutics Development 9 Pipeline Products for Chemotherapy Induced Anemia - Overview 9 Chemotherapy Induced Anemia - Therapeutics under Development by Companies 10 Chemotherapy Induced Anemia - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Chemotherapy Induced Anemia - Products under Development by Companies 15 Chemotherapy Induced Anemia - Companies Involved in Therapeutics Development 16 3SBio Inc. 16 BIOCAD 17 Chong Kun Dang Pharmaceutical Corp. 18 Dr. Reddy's Laboratories Limited 19 Galenica Ltd. 20 Panacea Biotec Limited 21 Pfizer Inc. 22 PharmaEssentia Corporation 23 PhytoHealth Corporation 24 Pieris Pharmaceuticals Inc 25 Sandoz International GmbH 26 SBI Pharmaceuticals Co., Ltd. 27 Therapure Biopharma Inc. 28 Tolero Pharmaceuticals, Inc. 29 Chemotherapy Induced Anemia - Therapeutics Assessment 30 Assessment by Monotherapy Products 30 Assessment by Combination Products 31 Assessment by Target 32 Assessment by Mechanism of Action 34 Assessment by Route of Administration 36 Assessment by Molecule Type 38 Drug Profiles 40 (aminolevulinic acid hydrochloride + sodium ferrous citrate) - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 darbepoetin alfa - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 darbepoetin alfa - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 darbepoetin alfa - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 darbepoetin alfa - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 darbepoetin alfa - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 epoetin alfa - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 epoetin zeta - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 ferric carboxymaltose - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 P-1116 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 PHN-013 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 PRS-080 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 SSS-06 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 TBI-304H - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 TP-0184 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 TP-0413 - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 TXA-302 - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 Chemotherapy Induced Anemia - Dormant Projects 63 Chemotherapy Induced Anemia - Discontinued Products 64 Chemotherapy Induced Anemia - Product Development Milestones 65 Featured News & Press Releases 65 Mar 11, 2015: Therapure Innovations Receives FDA Approval to Proceed with a Phase 1 Clinical Trial of Its Novel Anemia Therapeutic TBI 304H 65 Oct 30, 2012: SBI Pharmaceuticals Submits a Phase-1 Clinical Trial CTA to MHRA for a Drug to Treat Cancer Chemotherapy-induced Anemia 65 Apr 24, 2012: SBI Pharmaceuticals Announces Obtainment of Marketing Authorization of Products Containing 5-ALA from The Kingdom of Bahrain Ministry of Health 65 Oct 28, 2011: ALA Study Results Presented at the 49th Annual Meeting of Japan Society of Clinical Oncology 66 Oct 05, 2011: ALA Study Results Presented at Japanese Cancer Association, 70th Annual Meeting 66 Mar 18, 2011: Announcement of publication of ALA research in International Immunopharmacology 67 Sep 30, 2010: Safety study for subcutaneous epoetin alfa biosimilar Binocrit/Epoetin alfa Hexal/Abseamed suspended 67 Aug 09, 2010: Dr Reddy's Launches Darbepoetin Alfa For Treatment Of Anemia In India 68 Dec 01, 2008: International presentation of clinical safety and efficacy data for Binocrit, the world's first complex biosimilar 68 Jan 07, 2008: Sandoz and Gambro form strategic alliance 69 Aug 31, 2007: European Commission approves Sandoz's epoetin alfa Binocrit 69 Appendix 70 Methodology 70 Coverage 70 Secondary Research 70 Primary Research 70 Expert Panel Validation 70 Contact Us 70 Disclaimer 71
List of Tables
Number of Products under Development for Chemotherapy Induced Anemia, H2 2016 9 Number of Products under Development by Companies, H2 2016 11 Comparative Analysis by Late Stage Development, H2 2016 12 Comparative Analysis by Clinical Stage Development, H2 2016 13 Comparative Analysis by Early Stage Development, H2 2016 14 Products under Development by Companies, H2 2016 15 Chemotherapy Induced Anemia - Pipeline by 3SBio Inc., H2 2016 16 Chemotherapy Induced Anemia - Pipeline by BIOCAD, H2 2016 17 Chemotherapy Induced Anemia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016 18 Chemotherapy Induced Anemia - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016 19 Chemotherapy Induced Anemia - Pipeline by Galenica Ltd., H2 2016 20 Chemotherapy Induced Anemia - Pipeline by Panacea Biotec Limited, H2 2016 21 Chemotherapy Induced Anemia - Pipeline by Pfizer Inc., H2 2016 22 Chemotherapy Induced Anemia - Pipeline by PharmaEssentia Corporation, H2 2016 23 Chemotherapy Induced Anemia - Pipeline by PhytoHealth Corporation, H2 2016 24 Chemotherapy Induced Anemia - Pipeline by Pieris Pharmaceuticals Inc, H2 2016 25 Chemotherapy Induced Anemia - Pipeline by Sandoz International GmbH, H2 2016 26 Chemotherapy Induced Anemia - Pipeline by SBI Pharmaceuticals Co., Ltd., H2 2016 27 Chemotherapy Induced Anemia - Pipeline by Therapure Biopharma Inc., H2 2016 28 Chemotherapy Induced Anemia - Pipeline by Tolero Pharmaceuticals, Inc., H2 2016 29 Assessment by Monotherapy Products, H2 2016 30 Assessment by Combination Products, H2 2016 31 Number of Products by Stage and Target, H2 2016 33 Number of Products by Stage and Mechanism of Action, H2 2016 35 Number of Products by Stage and Route of Administration, H2 2016 37 Number of Products by Stage and Molecule Type, H2 2016 39 Chemotherapy Induced Anemia - Dormant Projects, H2 2016 63 Chemotherapy Induced Anemia - Discontinued Products, H2 2016 64
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
